In short
This article discusses the clinical trials of EO2463, an innovative cancer vaccine therapy being studied for the treatment of indolent Non-Hodgkin's Lymphoma (NHL). The trials aim to evaluate the safety, efficacy, and optimal dosing of EO2463 when used alone or in combination with other treatments like lenalidomide and rituximab. The study focuses on patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL), two subtypes of indolent NHL.
At a glance
- Drug Name
- EO2463
- Drug Type
- Novel microbial-derived peptide therapeutic vaccine
- Target Condition
- Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
- Trial Phase
- Phase 1/2
- Administration
- Subcutaneous injection
- Combination Therapies
- Lenalidomide and/or Rituximab (in some cohorts)
- Primary Objectives
- Determine recommended Phase 2 dose, assess safety, estimate objective response rate
- Key Eligibility Criteria
- Adults with FL or MZL, HLA-A2 positive, measurable disease
- Trial Duration
- 9-12 months active treatment, followed by short-term and long-term follow-up
What is EO2463?
EO2463 is a new type of cancer treatment called a microbial-derived peptide therapeutic vaccine. It is currently being studied for the treatment of certain types of indolent Non-Hodgkin's Lymphoma (NHL), specifically Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL).
This innovative therapy is composed of several peptides (small protein fragments) named OMP72, OMP64, OMP65, OMP66, and UCP2. These peptides are derived from microbes and have been designed to stimulate the immune system to fight against lymphoma cells.
Target Conditions
EO2463 is being developed to treat two specific types of indolent (slow-growing) Non-Hodgkin's Lymphoma:
- Follicular Lymphoma (FL): A type of lymphoma that develops from B-lymphocytes (a type of white blood cell) in the lymph nodes.
- Marginal Zone Lymphoma (MZL): This includes three subtypes:
- Extranodal MZL (EMZL, also known as MALT lymphoma)
- Splenic MZL (SMZL)
- Nodal MZL (NMZL)
These lymphomas are considered indolent because they tend to grow and spread slowly compared to more aggressive forms of lymphoma.
How EO2463 Works
EO2463 is designed to work as a therapeutic vaccine, meaning it aims to stimulate the patient's own immune system to fight against cancer cells. The peptides in EO2463 are thought to activate T cells (a type of immune cell) that can recognize and attack lymphoma cells.
Specifically, the vaccine is designed to target certain proteins found on B cells (the cells that become cancerous in FL and MZL), including CD20, CD22, CD37, and BAFF-receptor. By training the immune system to recognize these proteins, EO2463 may help the body identify and destroy lymphoma cells more effectively.
Clinical Trial Overview
EO2463 is currently being studied in a Phase 1/2 clinical trial. This trial aims to:
- Determine the safe and effective dose of EO2463 (Phase 1)
- Evaluate how well EO2463 works in treating indolent NHL (Phase 2)
- Assess the safety and effectiveness of EO2463 when used alone or in combination with other drugs (lenalidomide and rituximab)
The trial includes several different groups (cohorts) of patients, including both newly diagnosed and previously treated individuals with FL or MZL.
Eligibility Criteria
To participate in the EO2463 clinical trial, patients must meet certain criteria. Some key eligibility factors include:
- Age 18 or older
- Diagnosed with FL or MZL
- HLA-A2 positive (a specific genetic marker)
- Measurable disease (at least one lymph node or tumor mass ≥ 1.5 cm)
- For some cohorts, patients must have received prior treatment
- For other cohorts, patients must be newly diagnosed and untreated
There are also several exclusion criteria, such as certain medical conditions or prior treatments that would make a patient ineligible for the trial. It's important to discuss all eligibility criteria with a healthcare provider or clinical trial coordinator.
Potential Benefits and Risks
As with any experimental treatment, EO2463 may offer potential benefits but also carries risks:
Potential benefits:
- A new treatment option for patients with indolent NHL
- Possibility of stimulating the immune system to fight cancer
- Potential for fewer side effects compared to traditional chemotherapy
Potential risks:
- Unknown or unexpected side effects
- The treatment may not be effective for everyone
- Possible immune-related side effects
Administration and Treatment Schedule
EO2463 is administered as a subcutaneous injection (an injection under the skin). The exact treatment schedule varies depending on which cohort a patient is in, but generally includes:
- An initial period of EO2463 alone (monotherapy)
- Possible addition of other drugs (lenalidomide and/or rituximab) later in the treatment course
- Regular monitoring and follow-up visits
The active treatment period lasts between 9 to 12 months, followed by a period of follow-up to monitor long-term effects and outcomes.